Daniel Paris

Has grant

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Investigation of Mitochondrial Epigenetic Changes as a Biomarker for Gulf War Illness and an Outcome Measure in Response to Therapy

Open Date: 2020-09-15

Close Date: 2023-09-14

Grant: Close

Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

Open Date: 2018-09-30

Close Date: 2023-04-30

Grant: Close

Pre-clinical Development of a Therapeutic for Alzheimer's Disease

Open Date: 2011-09-01

Close Date: 2012-12-29

Grant: Close

Effect of Celastrol in a Transgenic Mouse Model of Alzheimer's Disease

Open Date: 2008-01-01

Close Date:

Articles (10)

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Ugo Lucca

Istituto di Ricerche Farmacologiche Mario Negri

ITALY

View details

Rita Banzi

Mario Negri Institute for pharmacological research

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniel Paris

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

Characterization of immune profile in an aging multiple sclerosis clinic population

A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice

MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer’s disease

Mural cell dysfunction leads to altered cerebrovascular tau uptake following repetitive head trauma

Novel, natural allosteric inhibitors and enhancers of Candida rugosa lipase activity

Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD

Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: Data from NILVAD

Apolipoprotein E isoforms differentially regulate matrix metallopeptidase 9 function in Alzheimer's disease

Neuronal Spleen tyrosine kinase (SYK) mediates cytokine release in Transgenic Tau P301S mice organotypic brain slice cultures

Nilvadipine suppresses inflammation via inhibition of P-SYK and restores spatial memory deficits in a mouse model of repetitive mild TBI

Collaborators (2)

Ugo Lucca

Rita Banzi

Make your next move.